99 related articles for article (PubMed ID: 21683963)
1. Alpha- and beta-synuclein expression in Parkinson disease with and without dementia.
Beyer K; Ispierto L; Latorre P; Tolosa E; Ariza A
J Neurol Sci; 2011 Nov; 310(1-2):112-7. PubMed ID: 21683963
[TBL] [Abstract][Full Text] [Related]
2. The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.
Beyer K; Domingo-Sàbat M; Santos C; Tolosa E; Ferrer I; Ariza A
Brain; 2010 Dec; 133(Pt 12):3724-33. PubMed ID: 20959308
[TBL] [Abstract][Full Text] [Related]
3. New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases.
Beyer K; Munoz-Marmol AM; Sanz C; Marginet-Flinch R; Ferrer I; Ariza A
Neurogenetics; 2012 Feb; 13(1):61-72. PubMed ID: 22205345
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.
Quinn JG; Coulson DT; Brockbank S; Beyer N; Ravid R; Hellemans J; Irvine GB; Johnston JA
Brain Res; 2012 Jun; 1459():71-80. PubMed ID: 22560502
[TBL] [Abstract][Full Text] [Related]
5. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology.
Tsuboi Y; Uchikado H; Dickson DW
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S221-4. PubMed ID: 18267239
[TBL] [Abstract][Full Text] [Related]
6. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
Baba M; Nakajo S; Tu PH; Tomita T; Nakaya K; Lee VM; Trojanowski JQ; Iwatsubo T
Am J Pathol; 1998 Apr; 152(4):879-84. PubMed ID: 9546347
[TBL] [Abstract][Full Text] [Related]
7. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression.
Fan Y; Limprasert P; Murray IV; Smith AC; Lee VM; Trojanowski JQ; Sopher BL; La Spada AR
Hum Mol Genet; 2006 Oct; 15(20):3002-11. PubMed ID: 16959793
[TBL] [Abstract][Full Text] [Related]
8. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
11. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies.
Beyer MK; Larsen JP; Aarsland D
Neurology; 2007 Aug; 69(8):747-54. PubMed ID: 17709706
[TBL] [Abstract][Full Text] [Related]
12. Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson's Disease.
Marsal-García L; Urbizu A; Arnaldo L; Campdelacreu J; Vilas D; Ispierto L; Gascón-Bayarri J; Reñé R; Álvarez R; Beyer K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33450872
[TBL] [Abstract][Full Text] [Related]
13. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
[TBL] [Abstract][Full Text] [Related]
14. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
Iwatsubo T
Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
[TBL] [Abstract][Full Text] [Related]
15. Interaction between α-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and α-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.
Jellinger KA
Exp Neurol; 2011 Jan; 227(1):13-8. PubMed ID: 20965169
[TBL] [Abstract][Full Text] [Related]
16. Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease.
Beyer K; Humbert J; Ferrer A; Lao JI; Carrato C; López D; Ferrer I; Ariza A
Neuroreport; 2006 Aug; 17(12):1327-30. PubMed ID: 16951579
[TBL] [Abstract][Full Text] [Related]
17. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
18. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.
Fujishiro H; Iseki E; Higashi S; Kasanuki K; Murayama N; Togo T; Katsuse O; Uchikado H; Aoki N; Kosaka K; Arai H; Sato K
Neurosci Lett; 2010 Dec; 486(1):19-23. PubMed ID: 20851165
[TBL] [Abstract][Full Text] [Related]
19. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.
Sasaki K; Doh-ura K; Wakisaka Y; Iwaki T
Acta Neuropathol; 2002 Sep; 104(3):225-30. PubMed ID: 12172907
[TBL] [Abstract][Full Text] [Related]
20. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
Iwatsubo T
J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
